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384Primary stenting of femoropopliteal atherosclerotic
lesions using new helical interwoven nitinol stents
Yiu Che Chan, MBBS, BSc, MD, FRCS, Stephen W. Cheng, MS, FRCS, Albert C. Ting, MS, FRCS, and
Grace C. Cheung, MMedSc, Hong Kong
Background: The Supera helical interwoven nitinol stent has enhanced ﬂexibility in counteracting fractures when placed in
the femoropopliteal arteries and may improve patency. The aim of this study is to assess the early results of the Supera
stent in symptomatic patients with femoropopliteal atherosclerotic lesions.
Methods: From October 2011 to April 2013, patients with symptomatic femoropopliteal lesions were treated with
angioplasty and primary stenting using the Supera stent. They were followed up at 1, 3, 6, and 12 months with clinical,
duplex, and radiographic assessments. Failure was deﬁned as >50% restenosis of the target lesion on duplex ultrasound
imaging or stent fracture on X rays.
Results: A total of 78 consecutive patients (46 males, 32 females) with 82 legs, mean age of 78.5 years (range, 57-97 years)
were included. Symptoms of claudication, rest pain, and tissue loss were 48 (59%), 8 (10.1%), and 30 (37%), respectively.
Ninety-six Supera stents were inserted in total. In 44 (53.7%) of the legs, stents were extended to the popliteal segments.
The mean stented length was 12.6 cm (range, 4.0-38.0 cm). The primary patency rates at 6 and 12 months were 83.5%
and 78.6%, respectively. The ankle brachial index increased from 0.58 6 0.16 preoperative to 0.87 6 0.14 postoperative.
There were no stent fractures. Patency rate was not affected by severity of symptoms, stent lengths, femoro/popliteal
stents (log-rank test, P[ .50, .13, .52). All the patients reported symptomatic improvement. There was no procedural- or
device-related morbidity or mortality, no major amputation after revascularization, and 10 patients died of unrelated
cardiopulmonary/renal causes on follow-up.
Conclusions: Our early experience shows that the Supera stents are effective in our cohort of elderly patients, with
acceptable patency rates. There were no stent fractures so far even with stenting of the popliteal segments. (J Vasc Surg
2014;59:384-91.)Implantation of nitinol stents into the superﬁcial
femoral and popliteal arteries is a widely used technique,
either as a selective or routine adjunct to percutaneous
transluminal angioplasty.1-3 Stents placed in the lower
limb arteries, especially those near the hip or knee joints,
may fracture over time and can damage the artery and cause
restenosis or occlusion. Stent fracture rates may vary from
10%4 to 37.2%5 depending on different cohort series.
The Supera (IDEV Technologies Inc, Houston, Tex)
stent consists of six pairs of closed end interwoven nitinol
wires and is delivered via a co-axial catheter-based delivery
handle. The helical structure, which is designed to adapt tothe Division of Vascular and Endovascular Surgery, Department of
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and kink resistance. It was formally launched in Leipzig,
Germany, in 2010 with a full launch in Europe in the
summer of 2010, and the ﬁrst case in Asia was performed
at our institution in October 2011. In the United States,
it received the U.S. Food and Drug Administration
(FDA) 510(k) clearance for palliative treatment of biliary
strictures produced by neoplasms in 2008 and can only
be used for peripheral vascular as a FDA investigational
device exemption trial setting. Furthermore, because of
a reduction of cell interconnections and a more spiral
orientation of the interconnections, this stent may resist
fracture as a result of repetitive metal strain. As this is
a new product, there are as yet few published series on
the clinical follow-up. The helical structure has been shown
to improve radial strength, ﬂexibility, and kink resistance
and is designed to adapt to the arterial anatomy. The aim
of this prospective study is report our experience in using
this Supera stent, a helical interwoven nitinol stent, in treat-
ing patients with symptomatic superﬁcial femoral and
popliteal arterial disease.
METHODS
Study population. Patients of Chinese ethnicity who
presented to our tertiary vascular and endovascular center
with symptomatic peripheral arterial disease were consid-
ered for this study. All the patients underwent preoperative
arterial duplex by qualiﬁed vascular technologist ultraso-
nographers in our dedicated vascular center. The duplex
Fig 1. Example of popliteal angioplasty and stent placement.
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of target lesion. In our institution, we routinely relied on
accurate duplex ultrasound report of peripheral arterial
system prior to intervention, without conﬁrming with
another imaging modality.
All the patients gave written consent. Patients with
lower limb femoropopliteal arterial stenoses or occlusions,
as shown on preoperative duplex ultrasound assessment,
were included in this study, with an “intention-to-treat”
paradigm. Patients with acute thrombus or aneurysm in
the index vessel, unsalvageable limb, poor inﬂow or total
absence of runoff vessels, lesions unsuitable for angioplasty,
very limited life-expectancy, or doubts in the willingness or
capability to allow follow-up examination were excluded.
Patients with renal impairment who were deemed very
high risk of developing contrast nephropathy would be opti-
mized as much as possible and those who could not tolerate
the intervention or subsequent follow-up were excluded.
There was no deliberate selection bias by the authors to
only insert Supera stents in cases with favorable lesions,
and all patients followed a ﬁxed protocol of follow-up.
Revascularization procedure. All patients had initial
diagnostic angiography of the lower limb with standard
contrast intra-arterial digital subtraction angiogram to
outline the vascular anatomy and deﬁne the lesion char-
acteristics and to conﬁrm their candidacy for the study. The
endovascular procedures were performed by experienced
vascular specialists in a hybrid endovascular suite (Siemens
Artis Zee Multipurpose System; Siemens, Munich,
Germany). All patients were on aspirin preoperatively. The
procedures were performed under monitored anesthetic
care or under local anesthesia, with ipsilateral or contra-
lateral common femoral artery accessed with a 6F sheathfor the diagnostic angiogram. All the patients received
intra-arterial heparin through the sheath. All patients were
on clopidogrel and aspirin for 3 months and remained on
aspirin for life.
From the intraoperative angiogram, it was possible to
calculate and document the diameter of the target vessel,
the minimal luminal diameter, minimal luminal area, and
the length of stenosis/occlusion. Stenoses and occlusions
were passed using a 0.035- or 0.018-inch guidewire with
the help of a 5F straight diagnostic catheter. Angioplasty
balloon catheters ranging in size from 4 to 7mm in diameter
by 20 to 200 mm in length were inﬂated to nominal atmo-
spheres for 1 minute. All Supera (IDEV Technologies Inc)
stented target lesions were angioplastied with the balloon
size 1 mm larger than the stent diameter as per manufac-
turer’s instructions, with poststent dilatation. Stents were
chosen to cover the length of the lesions (Fig 1).
Postprocedure assessment and follow-up. Clinical
evaluation with ankle brachial index assessment of adverse
events was planned predischarge from hospital. Clinical
follow-up and duplex ultrasound for evaluation of reste-
nosis will be performed routinely on all the patients at 1, 3,
6, and 12 months. Plain radiographs of the stent (Fig 2)
will also be taken at 3, 6, and 12 months to rule out any
fracture of the stent. All our patients had electronic
radiological records on Clinical Management System-
Electronic Patients Records. The plain radiographs of the
stents were taken as anteroposterior and lateral views, and
viewed on the Centricity Enterprise Web Listener 1.0 (GE
Healthcare Products). The ﬁlms can be magniﬁed on
screen during viewing.
The primary end points were limb salvage (freedom
from above-knee and below-knee amputations) and
Fig 2. Plain radiographs of the stents postprocedure to detect fractures.
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and 12 months were evaluated with duplex ultrasound by
vascular ultrasonographers. We deﬁne postoperative reste-
nosis (loss of primary patency) as target lesion restenosis
of $50% or occlusion. The ultrasound criteria used for
a restenosis greater than 50% was prestenosis and at-
stenosis ratio of more than or equal to 2.0, or a peak
systolic velocity of more than or equal to 200 cm/s.
Improvement of symptoms, major amputations, stent-
related fractures, and all serious adverse events such as
mortality were also recorded.
Statistical analysis. Patency rates were analyzed using
Kaplan-Meier curves to compute time-to-event rates. The
log-rank test assessed the potential effect of risk factors on
outcome or complications in the univariate setting. A
multivariate model of the Cox-regression analyzed the
effect of potential risk factors and their interactions. Risk
stratiﬁcation for restenosis was also calculated. A P value of
#.05 was taken to be statistically signiﬁcant. All statistical
analyses were performed using SPSS software v. 20 (SPSS
Inc, Chicago, Ill).
RESULTS
Patient characteristics. From October 2011 to April
2013, 78 consecutive patients (46 males, 32 females)
with 82 legs with symptomatic femoropopliteal lesions
were treated with angioplasty and primary stenting using
the Supera stent at our institution. Forty-two were left-
sided lesions, 40 were right-sided lesions, and four patients
have bilateral interventions. For male patients, the mean
age of hospital admission was 74.4 years, with a range from
57 to 92. For female patients, the mean age of admission
was 84.4 years, with a range from 68 to 97. Our cohort of78 patients included some elderly patients, and the mean
age was 78.5 years (range, 57-97 years). Cardiovascular risk
factors were prevalent; 82% (67 patients) were on antihy-
pertensive medication, 44% (36 patients) were active
smokers, 56% (46 patients) were diabetic, and 37% (30
patients) had proven hyperlipidemia (Table I).
Indications for interventions included 47 (57%) cases
attributable to intermittent claudication, six (7%) cases
had rest pain, and 29 (35%) cases had tissue loss. Clinical
symptomatology of intermittent claudication can further
be categorized into ﬁve (6%) cases having mild claudication
(could walk more than 300 m), seven (9%) cases having
moderate claudication (could walk between 100 and
300 m), and 35 (43%) cases having severe claudication
(could walk less than 100 m) (Table I).
Lesions and procedural characteristics. All the
procedures were achieved with percutaneous endovascular
procedures, with only one patient requiring open explora-
tion of the common femoral artery performed under
general anesthesia with patch angioplasty in conjunction
with angioplasty and stenting of the superﬁcial femoral
artery (SFA) in view of severely calciﬁed common femoral
artery. All the puncture sites had manual compression for
20 minutes postprocedure. Lesion characteristics and
number of runoff vessels are summarized in Table I,
with 39 (48%) cases involving the proximal SFA, 56 (68%)
cases involving the mid-SFA, 60 (73%) cases involving the
distal-SFA, 44 (54%) cases involving the above-knee
popliteal artery, and 10 (12%) cases involving the below-
knee popliteal artery. The length of popliteal lesions
(which may extend to distal SFA) varied from 15 to
340 mm, with a mean of 139.3 mm. Six popliteal cases
had restenosis (3, 100%; 1, 70%; 2, 50%). For these
Table I. Prevalence of cardiovascular risk factors in
cohort of 78 patients with their symptoms at presentation
Variable
No. of
patients % (n ¼ 78)
Prevalence of cardiovascular
risk factors
Smoking 34 44
Hypertension 64 82
Hyperlipidemia 28 36
Diabetes 44 56
Variable No. of cases % (n ¼ 82)
Symptoms of patients
Mild claudication 5 6
Moderate claudication 7 9
Severe claudication 35 43
Ischemic rest pain 6 7
Tissue loss 29 35
Diseased segment
Proximal SFA 39 48
Mid SFA 56 68
Distal SFA 60 73
Popliteal - above knee 44 54
Popliteal - below knee 10 12
TASC II classiﬁcation
A 22 27
B 40 49
C 19 23
Occluded lesions were found in 24 cases.
No. of vessel(s) runoff
0 2 2
1 28 34
2 28 34
3 24 29
TASC, TransAtlantic Inter-Society Consensus; SFA, superﬁcial femoral
artery.
This table also gives the lesion characteristics including diseased segment,
TASC classiﬁcation, and number of runoff vessels.
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month patency was 73.0%.
A total of 96 stents, 4 to 6 mm diameter and 40 to
200 mm (each stent) were implanted in 78 patients. The
mean length of the stented artery was 126.1 mm (range,
40-380 mm; standard error of the mean, 7.63) for mean
length of lesion of 110 mm (range, 10-310 mm; standard
error of the mean, 8.22). All the lesions had poststent
moulding. Technical success was 100%.
Patient follow-up. The mean follow-up period was
7.28 months for 76 patients. There were no perioperative
or procedural/device-related mortality. One patient
developed a 1.5-cm pseudoaneurysm in the groin, which
was treated conservatively. One patient had emboli to
peroneal artery requiring intraoperative on-table throm-
bolysis. On follow-up, a total of 12 (14.6%) patients (ﬁve
male, seven female) had died. The majority of the patients
who died were elderly and died of unrelated cardiopul-
monary causes beyond 30 days: seven patients from
pneumonia, two from cardiac, one from cardiac and renal
causes, and one from gastrointestinal bleed. There was onlyone 30-day mortality of a 93-year-old lady with tissue loss,
and she underwent a successful revasularization and was
discharged on day 4 after a successful procedure but was
readmitted to hospital on day 10 with respiratory distress
after suddenly collapsing at home.
Ankle brachial index, stent patency, and stent
fracture rates. Limb salvage rate was 100% with none of
the patients having major (below-knee or above-knee)
amputations. Between baseline and discharge, the mean
ankle brachial index increased signiﬁcantly from 0.58 6
0.16 preoperatively to 0.87 6 0.14 postprocedure (P <
.01, paired t-tests), with all the patients reported
improvement in symptoms. All the patients followed the
set protocol, and the primary patency rate was 83.5% at
6 months and 78.6% at 12 months (Fig 3). The nine patients
who had in-stent restenosis or in-stent occlusion included
two with 50%, two with 70%, and two with 80% restenosis,
and three with reocclusion. Only one patient underwent
primary assisted revascularization, despite the fact that they
had recurrent claudication. The reason being the balloons
and stents were self-ﬁnanced items by the patients, and they
preferred a conservative nonintervention if their symptoms
improved. The primary patency rate is shown in Fig 3. Risk
factor stratiﬁcation for restenosis is shown in Table II, and
diabetes mellitus is the only signiﬁcant predictor for this
cohort of patients. The primary patency rate as analyzed by
the length of stents is shown in Fig 4. On follow-up of the
patients with a mean follow-up period, none of them
developed stent fracture on plain radiographs.
DISCUSSION
This article describes our initial experience on the
primary stenting using Supera stents (IDEV Technologies
Inc) for treating symptomatic patients with femoropopli-
teal atherosclerotic lesions. Our cohort of consecutive
patients included an elderly proportion, with 29 (35%)
having tissue loss. The majority of our patients had athero-
sclerotic disease involving the distal SFA and the popliteal
artery. Our primary patency rate of 78.6% (less than 50%
restenosis) at 12 months is comparable to the few pub-
lished series in the literature (Table III). In all of the
patients who followed the protocol and had biplaner radio-
graphs of the stents, none developed stent fractures on
follow-up.
Our study is one of the few among published series on
Supera stents. Scheinert et al reported 2-year results of 137
Supera stents in 107 consecutive patients with predomi-
nately SFA lesions. The stented segments had a mean
length of 111.50 mm, and the mean primary and
secondary stent patency rates at 6 and 12 months were
93.1%, 99.0%, 84.7%, and 94.8%, respectively. There
were no stent fractures seen in the 91 patients examined.6
Another study of 40 patients who underwent angioplasty
and Supera stenting of their popliteal arteries by Goltz
et al showed a 12-month primary and secondary patency
rates of 68.4% and 79.8%. respectively.7 In the Leipzig
Supera Popliteal Artery Stent Registry, Scheinert et al
studied 125 Supera stents in 101 consecutive patients
Fig 3. Primary patency rate on follow-up of 83.5% in 6 months and 78.6% in 12 months A, Primary patency rate
subgroup analyses as femoral/popliteal involvement. B and C, Primary patency rate subgroup analyses as claudication/
threatened limb as indication for treatment. POP, Popliteal artery; SFA, superﬁcial femoral artery.
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Table II. Risk factor stratiﬁcation for restenosis
No restenosis (n ¼ 73) Restenosis (n ¼ 9) Overall (n ¼ 82) P Test
Male sex 30 (41) 4 (44) 34 (41) 1.000 FET
Age, years 78.8 6 9.3 76 6 12.2 78.5 6 9.6 .412 t-test
Risk factors
Smoking 33 (45) 3 (33) 36 (44) .724 FET
Hypertension 59 (81) 8 (89) 67 (82) 1.000 FET
Hyperlipidemia 27 (37) 3 (33) 30 (37) 1.000 FET
Diabetes 38 (52) 8 (89) 46 (56) .070 FET
Symptoms
Claudication 44 (60) 4 (44) 48 (59) .478 FET
Rest pain 7 (10) 1 (11) 8 (10) 1.000 FET
Tissue loss 26 (36) 4 (44) 30 (37) .718 FET
Clinical group .486 FET
Claudicants 43 (59) 4 (44) 47 (57)
Threatened limb loss 30 (41) 5 (56) 35 (43)
Maximum stenosis 88.3 6 10.9 89.4 6 11.8 88.4 6 10.9 .766 t-test
Calciﬁcation 16 (22) 2 (22) 18 (22) 1.000 FET
Runoff vessels .734 Pearson’s c2
0 2 (3) 0 (0) 2 (2)
1 25 (34) 3 (33) 28 (34)
2 24 (33) 4 (44) 28 (34)
3 22 (30) 2 (22) 24 (29)
Combined length of stents 127.3 6 70.2 116.7 6 61.8 126.1 6 69.1 .667 t-test
No restenosis (n ¼ 72) Restenosis (n ¼ 9) Overall (n ¼ 81) P Test
TASC II classiﬁcation .755 Pearson’s c2
A 20 (28) 2 (22) 22 (27)
B 36 (50) 4 (44) 40 (49)
C 16 (22) 3 (33) 19 (23)
Length of lesion 112.5 6 74.4 140.8 6 101.7 115.6 6 77.7 .306 t-test
No restenosis (n ¼ 57) Restenosis (n ¼ 5) Overall (n ¼ 62) P Test
Pre-op ABI 0.6 6 0.2 0.6 6 0.2 0.6 6 0.2 .841 t-test
ABI, Ankle brachial index; FET, Fisher’s exact test; TASC, TransAtlantic Inter-Society Consensus.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
Fig 4. Primary patency rate subgroup analyses as length of stent
used.
Table III. Table summarizing published cohort studies
on Supera stents
Author No.
Femoro/
popliteal
6 months,a
%
12 months,a
%
Scheinert 20116 107 Femoral 93.1 84.7
Goltz 20127 40 Popliteal e 68.4
Scheinert 20138 101 Popliteal 94.6 87.7
Leon 20139 34 Popliteal 88.1 79.2
This paper 82 Femoropopliteal 83.5 78.6
aPrimary patency rates.
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6- and 12-month primary patency rates were 94.6% and
87.7%, respectively.8 Recently, Leon et al reported the
initial U.S. experience of 39 popliteal Supera stents in34 patients and showed primary, primary-assisted, and
secondary patency rates by duplex ultrasound imaging
were 79.2%, 88.1%, and 93%, respectively.9 In this study,
the mean clinical follow-up was 12.7 (range, 0-33.7)
months, and the average duplex and radiographic imaging
follow-up was 8.4 (range, 0-26.8) months. In this cohort
of patients, there were six instances of stent occlusion,
and six patients had hemodynamically signiﬁcant in-stent
stenosis; overall resulting in three patients sustained limb
loss, and an overall mortality of 8.8% during the study
JOURNAL OF VASCULAR SURGERY
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summarized in Table III.
Apart from published papers, there are other abstracts
published. Rosenﬁeld et al presented the 12-month
outcomes of the Supera Peripheral Stent System in October
2012 at the Tenth Vascular InterVentional Advances
Conference in October 2012. This SUPERB (Comparison
of the SUPERA PERipheral System to a Performance
Goal Derived from Balloon Angioplasty Clinical Trials in
the Superﬁcial Femoral Artery) study is an FDA-approved
investigational device exemption trial (ClinicalTrials.gov
Identiﬁer: NCT00933270)10,11 to evaluate the Supera stent
in treating patients with obstructive SFA in 264 patients in
34 centers, treating 266 lesions with a mean length of
8 cm. Primary patency at 1 year was 86% with no reported
stent fractures at 1 year. The 2-year clinical outcomes of
the Supera Peripheral Stent System from Supera 500,
a long-term registry, which was also presented at the Tenth
Vascular InterVentional Advances Conference by Scheinert
et al.12 This registry included 495 patients with 528 lesions,
with 53% of the patients with occlusive disease, and a mean
stented segment length of 12.6 cm. The primary end points
at 1 and 2 years were 84.1% and 73.0%, respectively.
Stents placement at the femoropopliteal junction and
proximal/mid-popliteal artery are not widely accepted by
many vascular specialists because of the biomechanical
forces over the knee joint can predispose to stent fracture
and restenosis.13-15 The femoropopliteal arterial segment,
especially the part behind the knee joint (known to be
exposed to many mechanical inﬂuences such as crossing of
ﬂexion points as well as interaction with the surrounding
musculature and the artery) is constantly exposed to relevant
external forces, including compression, torsion, and elonga-
tion during locomotion. In a large prospective series with 121
cases in which different types of uncovered nitinol stents were
used, Scheinert et al reported stent fractures in 37% (45 out of
121 legs had 64 fractures) after a mean follow-up of
11months.5 The stent fractures in this series ranged from frac-
ture of single struts to complete separation of stent segments,
and about one-third of the cases resulted in occlusion of the
artery. Stent fractures can also cause restenosis with signiﬁ-
cantly lower primary patency rate, although fractures without
causing hemodynamic signiﬁcance may run a more benign
course and may not need reintervention. Stent fractures may
damage the arterial wall and result in development of a pseu-
doaneurysm.16 Chang et al17 retrospectively reviewed 18
patients who underwent stent placement in popliteal arteries
and found that one limb had stent fracture at 1 month and
seven limbs developed fractures at the 3-month follow-up.
At 2-year follow-up, there were just four limbs, which did
not have stent fracture. The primary patency was much lower
in fractured stents. In our study and in the three series pub-
lished so far,6-8 there was no stent fracture reported.
The unique design of the Supera stent and its combina-
tion of ﬂexibility and radial strength may account for this
stent’s ability to restore durable patency. Varghese et al
had used this stent to reinforce the conformability and to
increase the radial strength of a Viabahn (W.L. Gore andAssociates, Flagstaff, Ariz) covered stent in the treatment
of a popliteal aneurysm, in covering both the proximal
and distal edges across the knee joint.18 According to the
manufacturers’ information, the Supera stent showed
increased ﬂexibility, duration, and radial force as a result
of its new design. The radial force of the Supera stent at
a diameter of 4-5 mm could be as much as 18 pounds.19
Because of these properties, case reports have showed
that the Supera stent can be used as a bail-out option in
an occluded popliteal segment with a fractured stent in
situ.20 It could also be used in an occluded SFA compli-
cated by a previously implanted, fractured standard stent.21
One of the limitations to our study is that it was a single
vascular center experience. Our study has a high proportion
of patients with critical limb ischemia, and many of the
patients are elderly. We regard our initial results as being
as accurate as possible, and the primary Supera stenting
was encouraging with no clinical limb loss, no device-
related morbidity/mortality, and no stent fractures. Since
there is as yet little long-term experience with this new
helical stent worldwide, we recommended continuous
surveillance of the treated segment with color-coded
Doppler sonography. However, the number of patients
studied is relatively small and lacks randomization. There
will inevitably be patient selection bias, which may have
inﬂuenced the results.
Internationally, there are ongoing studies on the
Supera stents such as the multicenter nonrandomized
observational STRONG (Supera Treatment Registry
Observing Neointimal Growth) Registry evaluating long
term outcomes of patients implanted with the Supera stent
in the SFA or popliteal arteries.22 The RAPID (Random-
ized trial of Leg ﬂow Paclitaxel-eluting balloon (LPEB)
with stent placement vs standard PTA with stent placement
for the treatment of intermediate (>5cm and >15cm) and
long (>15cm) lesions of the SFA) trial is a Dutch multi-
center, randomized, controlled patient, blind trial that
aims to recruit 176 patients with atherosclerotic lesions in
the SFA and randomly allocated for treatment with Leg-
ﬂow paclitaxel/shellac-coated balloons (Cardionovum
Sp.z.o.o., Warsaw, Poland) with Supera stenting or
uncoated balloon angioplasty with Supera.23
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